Jeffrey W. Allen

ORCID: 0000-0001-8766-064X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Neonatal Health and Biochemistry
  • Lung Cancer Treatments and Mutations
  • Heme Oxygenase-1 and Carbon Monoxide
  • Pain Mechanisms and Treatments
  • Mercury impact and mitigation studies
  • Metabolism and Genetic Disorders
  • Lung Cancer Diagnosis and Treatment
  • Lung Cancer Research Studies
  • Neuroscience and Neuropharmacology Research
  • Heavy Metal Exposure and Toxicity
  • Cancer Diagnosis and Treatment
  • Anesthesia and Neurotoxicity Research
  • Anesthesia and Pain Management
  • Pain Management and Opioid Use
  • Head and Neck Cancer Studies
  • Neuroendocrine Tumor Research Advances
  • Trace Elements in Health
  • Cancer therapeutics and mechanisms
  • Sulfur Compounds in Biology
  • nanoparticles nucleation surface interactions
  • Neonatal Respiratory Health Research
  • Radioactivity and Radon Measurements
  • Botulinum Toxin and Related Neurological Disorders
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Body Contouring and Surgery

Kootenai Medical Center
2017-2023

California Animal Hospital
2022

Alnylam Pharmaceuticals (United States)
2021

Eglin Air Force Base
2020

Southwestern Medical Center
2019

Inovio Pharmaceuticals (United States)
2019

The University of Texas Southwestern Medical Center
2019

Florida State University
2017

UC Davis Comprehensive Cancer Center
2014-2015

University of California, Davis
2014-2015

Febrile neutropenia, a common side effect of myelosuppressive chemotherapy in patients with cancer, can result prolonged hospitalization and broad-spectrum antibiotic use, often prompting treatment delays or dose reductions drug regimens. Prophylactic use myeloid growth factors (mainly the colony-stimulating filgrastim pegfilgrastim) heightened risk reduce severity duration febrile neutropenia. The NCCN Clinical Practice Guidelines Oncology (NCCN Guidelines) for Myeloid Growth Factors...

10.6004/jnccn.2011.0075 article EN Journal of the National Comprehensive Cancer Network 2011-08-01

Background Despite the extensive use of intrathecal morphine infusion for pain, no systematic safety studies exist on its effects in high concentrations. The authors assessed and clonidine given 28 days intrathecally dogs. Methods Beagles with lumbar catheters received solutions delivered by a vest-mounted pump. Six groups (n = 3 each) infusions (40 microl/h) saline or 1.5, 3, 6, 9, 12 mg/day days. Additional at 40 microl/h (1.5 mg/day) plus (0.25-1.0 alone 100 microg/h (4.8 mg/day). Results...

10.1097/00000542-200307000-00028 article EN Anesthesiology 2003-07-01

Development of new therapies for previously treated small-cell lung cancer (SCLC) is a major unmet need. Here, we describe randomized, phase II trial weekly topotecan with or without ziv-aflibercept (VEGF-trap) in this clinical setting.

10.1200/jco.2013.51.4109 article EN Journal of Clinical Oncology 2014-07-08

Background Chronic intrathecal morphine infusion produces intradural granulomas. The authors examined a variety of opioids infused for analgesic activity and toxicity. Methods Two sets experiments were undertaken in dogs with chronic catheters: (1) Six-hour infusions used to determine the full dose maximum tolerated dose. (2) To establish toxicity, was given up 28 days by continuous infusion. Drugs sulfate, hydromorphone, D/L-methadone, L-methadone, D-methadone, fentanyl,...

10.1097/00000542-200609000-00025 article EN Anesthesiology 2006-08-24

Intrathecal morphine infusion leads to intrathecal granulomas. In dogs, the authors examined time course of granuloma formation and role concentration in development.Dogs were prepared with lumbar catheters vest-mounted pumps. To define formation, serial magnetic resonance imaging was performed animals receiving 10 or 31 days (12.5 mg/ml at 40 microl/h). At these times, removed from infusate, further images acquired over 14-35 additional days. assess dose versus concentration, dogs received...

10.1097/00000542-200609000-00024 article EN Anesthesiology 2006-08-24

Zika virus (ZIKV) infection is endemic to several world regions, and many others are at high risk for seasonal outbreaks. Synthetic DNA-encoded monoclonal antibody (DMAb) an approach that enables in vivo delivery of highly potent mAbs control infections. We engineered DMAb-ZK190, encoding the mAb ZK190 neutralizing antibody, which targets ZIKV E protein DIII domain. In vivo-delivered DMAb-ZK190 achieved expression levels persisting >10 weeks mice >3 non-human primate (NHPs), protective...

10.1016/j.ymthe.2019.03.005 article EN cc-by Molecular Therapy 2019-04-05

Abstract BACKGROUND: Curative treatment of early stage nonsmall cell lung cancer (NSCLC) requires good quality surgical resection (GQR). The degree compliance with national recommendations for GQR is poorly defined. We sought to quantitatively define the in a consecutive series NSCLC resections. METHODS: Medical records patients who underwent curative‐intent Memphis, TN metropolitan area from January 1, 2004 December 31, 2007 were retrospectively reviewed (N = 746 patients). criteria...

10.1002/cncr.25334 article EN Cancer 2010-08-24

The purpose of this chapter is to provide guidance the novice investigator as two models ongoing nociception in rats. described herein are formalin test, which an irritant injected subcutaneously into a dorsal paw and numbers flinches produced over 60 min counted, mild burn model that produces transitory primary secondary thermal mechanical hyperalgesia lasting approx 90 min. These allow assessment spinal sensitization, may be important factor when considering plasticity associated with...

10.1385/1-59259-770-x:189 article EN Humana Press eBooks 2004-01-01

Models of acute nociception using a thermal stimulus are widely employed as screening methods for nociceptive properties new drug compounds. In this chapter, detailed descriptions conducting two the most commonly used models; hot plate test and "Hargreaves test," described. These models applicable to both rats mice have advantage allowing repeated multiple testing single animal because is transitory produces no tissue damage. Additionally, modication these skin-twitch reflex that large...

10.1385/1-59259-770-x:139 article EN Humana Press eBooks 2004-01-01

Contulakin-G is a novel conopeptide with an incompletely defined mechanism of action. To assess nociceptive activity we delivered as bolus intrathecally (0.03, 0.1, 0.3, 3 nmol) or epidurally (10, 30, 89 in rats. Intrathecal Contulakin G significantly decreased Phase II and, to lesser degree, I paw flinching produced by intradermal formalin. and epidural doses ED50s were 0.07 nmol 45 nmol, respectively, giving epidural/intrathecal ED50 ratio = 647). In dogs, intrathecal (50-500 nmoL)...

10.1213/01.ane.0000219586.65112.fa article EN Anesthesia & Analgesia 2007-05-15

Intrathecal (IT) substance P-Saporin (SP-SAP), a 33-kDa–targeted neurotoxin, produces selective destruction of superficial neurokinin 1 receptor (NK1r)–bearing cells in the spinal dorsal horn. In rats, SP-SAP prevents formation hyperalgesia and can reverse established neuropathic pain behavior rodents. To determine safety this therapeutic modality large animal model, beagles received bolus IT lumbar injections vehicle, (1.5, 15, 45, or 150 μg), nontargeted preparation saporin (SAP, μg) for...

10.1093/toxsci/kfj143 article EN Toxicological Sciences 2006-02-24
Coming Soon ...